TABLE 2.
Anti-tetanus-toxoid antibody concentrations
| Groupa | Total
IgG
|
IgG1
|
Geometric mean (range) concn
(μg/ml) on the indicated day:
|
Geometric mean
(range) IgA concn (AU/ml) on the following day:
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IgG2
|
IgG3
|
IgG4
|
||||||||||||
| Geometric mean (range) concn (μg/ml) on the
following day:
|
FIb | Geometric
mean (range) concn (μg/ml) on the following
day:
|
FI | Day
|
Day
|
Day
|
||||||||
| 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | 0 | 30 | |||
| I | 4.4 (1.1–15.4) | 7.7c (2.7–21.9) | 2.0 (0.8–6.1) | 3.7 (1.1–12.2) | 6.6c (2.0–18.6) | 2.1 (0.7–6.0) | 0.2 (0.1–1.0) | 0.4d (0.1–1.5) | 0.4 (0.2–1.0) | 0.5d (0.2–1.2) | 0.1 (0.01–0.7) | 0.2 (0.05–1.1) | 3.9 (1.6–13.4) | 5.8 (2.2–20.1) |
| II | 6.5 (1.3–22.7) | 29.4 (12.7–62.9) | 9.4 (1.6–48.0) | 5.3 (1.1–20.4) | 25.5 (11.1–57.3) | 9.2 (1.8–41.0) | 0.4 (0.05–3.5) | 1.3 (0.4–7.0) | 0.6 (0.1–1.5) | 1.6 (0.7–4.9) | 0.2 (0.05–4.7) | 0.6 (0.05–8.2) | 4.0 (1.3–17.2) | 8.3 (4.6–13.3) |
| Control | 4.9 (1.0–22.6) | 40.1 (23.1–82.6) | 18.9 (1.3–55.1) | 5.8 (1.5–26.7) | 46.9 (28.3–92.3) | 19 (1.3–61.5) | 0.2 (0.1–0.3) | 0.7 (0.3–2.9) | 0.4 (0.1–1.6) | 0.9 (0.7–1.5) | 0.1 (0.05–0.1) | 0.3 (0.2–1.1) | 2.9 (1.1–8.8) | 14.3 (8.0–25.8) |
a
HIV-infected individuals with a CD4+ T-lymphocyte counts of <200 × 106/liter (group I; n = 13) and ≥200 × 106/liter (group II; n = 11) and healthy controls (group C; n = 5).
b
FI, fold increase in concentration is expressed as the ratio of the postvaccination concentration to the prevaccination concentration.
c
P < 0.05 compared with group II and controls.
d
P < 0.05 compared with group II.